Adma Biologics (ADMA) EBIAT (2016 - 2025)
Historic EBIAT for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $36.4 million.
- Adma Biologics' EBIAT rose 144.53% to $36.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $209.4 million, marking a year-over-year increase of 20741.36%. This contributed to the annual value of $197.7 million for FY2024, which is 80000.0% up from last year.
- As of Q3 2025, Adma Biologics' EBIAT stood at $36.4 million, which was up 144.53% from $34.2 million recorded in Q2 2025.
- Adma Biologics' 5-year EBIAT high stood at $111.9 million for Q4 2024, and its period low was -$25.0 million during Q1 2022.
- Moreover, its 5-year median value for EBIAT was -$6.8 million (2023), whereas its average is $6.8 million.
- Its EBIAT has fluctuated over the past 5 years, first plummeted by 4425.59% in 2023, then skyrocketed by 129996.1% in 2024.
- Adma Biologics' EBIAT (Quarter) stood at -$16.6 million in 2021, then rose by 26.54% to -$12.2 million in 2022, then tumbled by 44.26% to -$17.6 million in 2023, then surged by 734.15% to $111.9 million in 2024, then plummeted by 67.44% to $36.4 million in 2025.
- Its EBIAT was $36.4 million in Q3 2025, compared to $34.2 million in Q2 2025 and $26.9 million in Q1 2025.